Correction of Disease Related Anaemia of B-Chronic Lymphoproliferative Disorders by Recombinant Human Erythropoietin: Maintenance is Necessary to Sustain Response

References

• Pangalis GA, Boussiotis VA, Kittas Ch. Malignant disorders of small lymphocytes. Small lymphocytic lymphoma, lymphoplasmacytic lymphoma and chronic lymphocytic leukemia: Their clinical and laboratory relationship. Am J Clin Pathol 1993; 99, 402-408, 1993
   PubMed Web of Science ®Google Scholar
• Pangalis GA, Angelopoulou MK, Vassilakopoulos Thp Siakantaris MP, Kittas CH. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, lymphoplasmacytc lymphoma and Waldenstrom's macroglobulinemia: A clinical, morphologic and biologic spectrum of similar disorders. Semin Hematol 1999; 36: 104–114
   PubMed Web of Science ®Google Scholar
• Hallberg L, Harwerth HG, Vannoti A. Iron deficiency, pathogenesis, clinical aspects, therapy. Academic press, London 1970
   Google Scholar
• Rosse W, Bunn FH. Hemolytic anemia and acute blood loss. Harrison's Principles of Internal Medicine 14^th Edition. McGrawHill Companies, USA 1998
   Google Scholar
• Majumdar G, Brown S, Slater NG, Singh AK. Clinical spectrum of auto-immune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Leuk Lymphoma 1992; 9: 149–151
   Web of Science ®Google Scholar
• Diehl LF, Ketshum LH. Autoimmune disease and chronic lymphocytic leukemia: Autoimmune hemolytic anemia, pure red cell aplasia and autoimmune thrombocytopenia. Semin Oncol 1998; 25: 80–97
   PubMed Web of Science ®Google Scholar
• Means Rt Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80: 1639–1647
   PubMed Web of Science ®Google Scholar
• Lee GR. The anemia of chronic disease. Semin Hematol 1983; 20: 61–80
   PubMed Web of Science ®Google Scholar
• Siakantaris MP, Samaras IT, Angelopoulou MK, Kontopidou FN, Pangalis GA. The role of cytokines in the supportive care of oncology patients. Haema 1999; 2: 64–82
   Google Scholar
• Glapsy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Roj S. Impact of therapy with epoetin alfa on clinical outcome in patients with non-myeloid malignancies during cancer chmotherapy in community oncology practice. J Clin Oncol 1997; 15: 1218–1234
   PubMed Web of Science ®Google Scholar
• Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322: 1693–1699
   PubMed Web of Science ®Google Scholar
• Oster W, Herrmann F, Gamm H, Zeile G, Lindemann A, Mulelr G, Brune T, Kraemer HP, Mertelsmann R. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 1990; 8: 956–962
   PubMed Web of Science ®Google Scholar
• Pangalis GA, Poziopoulos Ch Angelopoulou MK, Siakantaris MP, Panayiotidis P. Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin. Br J Haematol 1995; 89: 627–629
   PubMed Web of Science ®Google Scholar
• Boussiotis VA, Panayiotidis PG, Pangalis GA. Prolonged intermittent chlorambucil administration in B-chronic lymphocytic leukemia: Experience from a Single Hematology Unit. Leuk Lymphoma 1991; 5: 113–117
   PubMed Web of Science ®Google Scholar
• Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jager G, Lemevel A, Najman A, Silingardi V, Spriano M, Van Hoof A, Ehmer B. Recombinat human erythropietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response. Blood 1995; 86: 4446–4453
   PubMed Web of Science ®Google Scholar
• Moullet I, Salles G, Ketterer N, Dumontent C, Bouafia F, Neidhart-Berard EM, Thieblemont C, Felman P, Coiffier B. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 1998; 9: 1109–1115
   PubMed Web of Science ®Google Scholar
• Conlan MG, Armitage JO, Bast M, Weisenburger DD. Clinical significance of hematologic parameters in non-Hodgkin's lymphoma at diagnosis. Cancer 1991; 67: 1389–1395
   PubMed Web of Science ®Google Scholar
• Beguin Y. Eryhtropoietin and the anemia of cancer. Acta Clin Belg 1996; 51: 36–52
   PubMed Web of Science ®Google Scholar
• Douglas SW, Adamson JW. The anemia of chronic disorders: Studies of marrow regulation and iron metabolism. Blood 1975; 45: 55–65
   PubMed Web of Science ®Google Scholar
• Finch CA. Erythropoiesis, erythropoietin and iron. Blood 1982; 60: 1241–1246
   PubMed Web of Science ®Google Scholar
• Yuji Sawabe, Kaoru Kikuno, Tohru Iseki, Shinji Lida, Hiroshi Yonemitsu. Serum erythropoietin values and serum iron status during chemotherapy for leukemia. Eur J Haematol 1998; 60: 315–316
   PubMed Web of Science ®Google Scholar
• Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced eryhtropoietin production. Blood 1992; 79: 1987–1194
   PubMed Web of Science ®Google Scholar
• Walker RH. Special report: Transfusion risks. Am J. Clin Pathol 1987; 88: 374–378
   PubMed Web of Science ®Google Scholar
• Barosi G, Cazzola M, De Vincentiis A, Grossi A, Tura S. Guidelines for the use of recombinant human erythropoietin. Haematologica 1994; 79: 526–533
   PubMedGoogle Scholar
• Angelopoulou MK, Siakantaris MP, Pangalis GA. Downstaging Rai stage III B-chronic lymphocytic leukemia (B-CLL) patients by the successful administration of recombinant human erythropoietin (r-HuEPO) could change the natural history of the disease. Blood 1998; 92: 273b
   PubMed Web of Science ®Google Scholar
• Leitgeb C, Perchertsrorfer M, Fritz F, Ludwig H. Quality of life in chronic anaemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994; 73: 2535–2542
   PubMed Web of Science ®Google Scholar
• Cella D. Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol 1998; 25: 3–46
   Google Scholar
• Littlewood TJ, Bajetta E, Cella D. Efficacy and quality of life outcomes of epoetin alfa in a double-blind, placebo-controlled multicenter study of cancer patients receiving non-platinum containing chemotherapy. J Clin Oncol 1999; 18: 574a
   Google Scholar
• Livngstone RB, Winer E, Cleeland CS. Once-weekly dosing of epoetin alfa is similar to three times weekly dosing in increasing hemoglobin and quality of life. J Clin Oncol 1999; 18: 574a
   Google Scholar
• Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84: 1056–1063
   PubMed Web of Science ®Google Scholar
• Beguin Y. Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol 1998; 25: 27–34
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ponchio L, Beguin Y. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders: Results of a phase I/II clinical trial. Blood 1992; 79: 29–37
   PubMed Web of Science ®Google Scholar
• Henry DH, Abels RI. Recombinant human eryhtropoietin in the treatment of cancer and chemotherapy-induced anaemia: Results of double-blind and open-label follow-up studies. J Clin Oncol 1994; 21: 21–28
   Google Scholar
• Henry DH. Epoetin alfa and high-dose chemotherapy. Semin Oncol 1998; 25: 54–57
   PubMed Web of Science ®Google Scholar
• Olivieri A, Offidani M, Cantosi I. Addition of erythropoietin to granulocyte colony-stimulating factor after priming chemotherapy advances hemopoietic progenitor moboilization. Bone Marrow Transplant 1995; 16: 765–770
   PubMed Web of Science ®Google Scholar